

Australian Healthcare

INDUSTRY UPDATE - 30 May 2023

VALUATION MULTIPLES

Forward EV / EBITDA Multiples (monthly to 29/04/2023) Source: FactSet Research Systems Inc.

Multiples in the Healthcare sector have increased over the period. At the end of April, the sector traded on a forward EV / EBITDA multiple of 8.9x, compared to the ASX200 on 8.6x.



Average Values and Trading Multiples (values as at 29/04/2023) Source: FactSet Research Systems Inc.

Subsector	Enterprise Value (\$ m)	EV/EBITDA FY2023	EV/EBIT FY2023	Price / Earnings FY2023
Aged Care	734	9.1x	20.1x	37.9x
Animal Health	171	7.5x	NA	10.3x
Biotech	166,018	25.5x	30.1x	37.1x
Hospitals & Clinics	46,350	10.3x	20.3x	29.0x
Medical Devices	1,575	NA	NA	NA
Healthcare	215,122	7.4x	17.3x	27.7x

Note: Multiples are based on the forward year of the unreported period, which for the majority of companies in the sector is FY2023. Difference in forward EV/EBITDA multiples between Figure and Table are representative of the timing difference between month-end result, and current day result.

Composition of companies in Sector Dashboards are updated every 6 months.

¹ The InterFinancial Healthcare Index set is an unweighted index comprising Healthcare sector related companies trading on the Australian Securities Exchange (ASX). Estimates are sourced from FactSet Research Systems Inc.



Australian Healthcare

INDUSTRY UPDATE - 30 May 2023

MERGER & ACQUISITION NEWS...



Value: Not Disclosed

A New Zealand based undisclosed Acquiror is to acquire Nursing Homes, the local two Auckland care sites from **Oceania Healthcare Ltd**, the local retirement village operator. The terms of the deal were undisclosed. The agreement is conditional on the purchaser obtaining the consent of the Ministry of Health and Te Whatu Ora to the transfer and the sale is expected to settle in August 2023.



Value: Not Disclosed

Henry Schein Inc, the United States based vendor of healthcare products to clinics has acquired **Regional Health Care Group Pty Ltd**, the Australia based distributor of dental products. The terms of the deal were undisclosed.

UNDER THE MICROSCOPE...

- Dexus [ASX:DXS], an Australian asset manager, today (4 May) announced that three of its funds have acquired a combined 30.58% interest in Celsus Holding Pty Ltd, the consortium that manages and maintains the Royal Adelaide Hospital under a Public-Private Partnership in Australia.
- · Private equity firm The Growth Fund, is seeking acquirers for Ekera Dental.



Australian Healthcare

INDUSTRY UPDATE - 30 May 2023

CONTACT DETAILS

If you are interested in specific information regarding mergers and acquisitions in the Healthcare sector, please contact David Hassum or Michael Kakanis.

Name	Position	Phone	Email
Sharon Doyle	Executive Chair	0411 055 666	sdoyle@interfinancial.com.au
Brad Shaw	Chief Executive Officer	0499 058 582	bshaw@interfinancial.com.au
Mark Steinhardt	Director - M&A	0403 628 842	msteinhardt@interfinancial.com.au
David Hassum	Director	0411 132 251	dhassum@interfinancial.com.au
Andrew Wheeler	Director	0438 316 716	awheeler@interfinancial.com.au
Kalum De Silva	Director	0414 685 903	kdesilva@interfinancial.com.au
Graeme McKellar	Managing Director – IFL Ventures	0416 428 993	graeme@iflventures.com
Michael Kakanis	Associate Director	0421 212 534	mkakanis@interfinancial.com.au
Anuk Manchanda	Associate Director	0434 087 673	amanchanda@interfinancial.com.au
Nimerta Kumari	Associate Director	0459 165 035	nkumari@interfinancial.com.au
Jenny Zeng	Associate Director – IFL Ventures	0452 473 536	Jenny@iflventures.com
isa McKellar	Associate Director – IFL Ventures	0404 085 342	lisa@iflventures.com
Maggie Liu	Associate	0401 459 719	mliu@interfinancial.com.au
Nasia Christodoulou	Research Assistant	0427 737 493	nchristodoulou@interfinancial.com.au

DISCLAIMER

This information has been sourced from the ASX, Mergermarket.com and various other public information sources. Forecasts are consensus forecasts sourced from FactSet Research Systems Inc.

Important Disclaimer – This may affect your legal rights: Because this document has been prepared without consideration of any specific person's financial situation, particular needs and investment objectives, a financial services licensee or investment adviser should be consulted before any investment decision is made. While this document is based on information from sources which are considered reliable, InterFinancial, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does InterFinancial accept any responsibility to inform you of any matter that subsequently comes to notice, which may affect any of the information contained in this document. This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of InterFinancial. This report does not constitute advice to any person.

Disclosure. InterFinancial has no interest in any of the securities mentioned in this publication. However, its directors, executives or consultants may have an interest in some of the securities, directly or indirectly, which are mentioned.

InterFinancial is a member of Clairfield International, an international corporate finance firm that provides advisory services in crossborder mergers and acquisitions. Clairfield is represented by over 400 people across 22 countries, closing over 100 transactions each year.

InterFinancial
Corporate Finance Limited
ABN: 49 136 962 966
AFSL: 341675
Level 2, 201 Chariotte Street
GPO Box 975
Brisbane Gueensland 4001
[07] 3218 9100
admin8interfinancial.com.au
www.interfinancial.com.au
www.interfinancial.com.au

